Accessibility Menu
Ionis Pharmaceuticals Stock Quote

Ionis Pharmaceuticals (NASDAQ: IONS)

$71.72
(-2.5%)
-1.83
Price as of October 21, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$71.72
Daily Change
(-2.5%) $1.83
Day's Range
$70.48 - $73.26
Previous Close
$71.72
Open
$73.09
Beta
0.84
Volume
71,414
Average Volume
2,470,157
Market Cap
11.4B
Market Cap / Employee
$71.64M
52wk Range
$23.95 - $74.42
Revenue
-
Gross Margin
0.97%
Dividend Yield
N/A
EPS
-$1.85
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Ionis Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
IONS+83.69%+51.81%+8.71%+636%
S&P+15.06%+95.03%+14.29%+1,709%

Ionis Pharmaceuticals Company Info

Ionis Pharmaceuticals is a biopharmaceutical company exploiting proprietary RNA-based drug discovery technologies to create a new class of drugs to treat important diseases.

News & Analysis

The Fool has written over 300 articles on Ionis Pharmaceuticals.

Financial Health

General

Q2 2025YOY Change
Revenue$452.05M100.7%
Gross Profit$445.03M106.5%
Gross Margin98.45%2.8%
Market Cap$6.29B-9.6%
Market Cap / Employee$5.88M0.0%
Employees1.1K15.3%
Net Income$123.55M286.4%
EBITDA$145.27M340.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$297.30M1.1%
Accounts Receivable$52.58M92.9%
Inventory8.5-70.5%

Liabilities

Q2 2025YOY Change
Long Term Debt$1.33B-31.1%
Short Term Debt$643.70M1349.1%

Ratios

Q2 2025YOY Change
Return On Assets-9.44%3.5%
Return On Invested Capital-16.33%-6.2%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$139.03M210.2%
Operating Free Cash Flow$151.34M226.2%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book9.548.338.1013.21-43.65%
Price to Sales7.417.836.677.63-10.75%
Price to Tangible Book Value9.548.338.1013.21-43.65%
Enterprise Value to EBITDA-38.10-49.45-32.5147.40-141.84%
Return on Equity-73.3%-93.0%-118.5%-59.8%-43.36%
Total Debt$1.98B$1.96B$1.96B$1.97B-0.11%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.